Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB8 vs Avastin in metastatic non-squamous NSCLC
NCT02754882Phase 3Completed
- Sponsor
- Samsung Bioepis
- Start
- Jul 2016
- Primary completion
- Jan 2018
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of bevacizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Samsung Bioepis. Primary endpoint: Best Overall Response Rate at 24 weeks. Started Jul 2016; status: completed.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02754882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02754882.